Back to Search
Start Over
The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study.
- Source :
-
Urologic oncology [Urol Oncol] 2012 Sep; Vol. 30 (5), pp. 704-10. Date of Electronic Publication: 2010 Oct 02. - Publication Year :
- 2012
-
Abstract
- Background: Several studies have reported unexpected rates of hypothyroidism in patients treated with sunitinib. The biochemical basis of this impairment is unknown. A relationship between hypothyroidism and improved outcome has been suggested in some cancer patients. Here we describe the incidence of newly onset hypothyroidism and its relationship with progression-free survival in metastatic renal cell carcinoma patients undergoing sunitinib treatment at our institution.<br />Patients and Methods: Between July 2007 and June 2009, 22 patients received a first line sunitinib for metastatic renal cell carcinoma. Thyroid function tests were prospectively evaluated as routine laboratory assessment in every patient, at baseline and on the first and last day of every ON and OFF sunitinib period.<br />Results: The median duration of treatment was 39.5 weeks. During sunitinib therapy, 13 patients (59.1%) showed at least one elevated TSH level. No reductions of TSH below normal ranges were observed. L-thyroxine replacement therapy was required in 2 patients. Based on thyroid function, median progression-free survival was 8.55 months for hypothyroid compared with 7.03 months for euthyroid patients (P < 0.05).<br />Conclusion: Patients administered sunitinib have an high incidence of hypothyroidism. The improved outcome of hypothyroid patients suggests an important relationship between sunitinib and this uncommon side effect.<br /> (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Subjects :
- Aged
Angiogenesis Inhibitors adverse effects
Angiogenesis Inhibitors therapeutic use
Carcinoma, Renal Cell pathology
Disease-Free Survival
Female
Humans
Hypothyroidism blood
Hypothyroidism chemically induced
Indoles adverse effects
Kaplan-Meier Estimate
Kidney Neoplasms pathology
Male
Middle Aged
Neoplasm Metastasis
Prospective Studies
Pyrroles adverse effects
Sunitinib
Thyroid Function Tests
Thyrotropin blood
Time Factors
Treatment Outcome
Carcinoma, Renal Cell drug therapy
Hypothyroidism pathology
Indoles therapeutic use
Kidney Neoplasms drug therapy
Pyrroles therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1873-2496
- Volume :
- 30
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Urologic oncology
- Publication Type :
- Academic Journal
- Accession number :
- 20884255
- Full Text :
- https://doi.org/10.1016/j.urolonc.2010.07.015